Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

"We were pleased to report a particularly strong quarter for product sales, which was driven by the continued strong performance of our Proprietary Medical Products, where we saw sales growth of 53% compared to the same period in 2008," said Dr. William Hunter, President and CEO of Angiotech. "We are particularly pleased by the continued success of our Quill(TM) SRS product line, which we believe will continue to be a strong performer during 2010."

    Fourth Quarter Financial Highlights

    -   Total revenue was $63.6 million.

    -   Net product sales were $50.0 million. Sales of our Proprietary
        Medical Products were $18.3 million, or 37% of total product sales.
        Sales of our Base Medical Products were $31.7 million, or 63% of
        total product sales.

    -   Royalty revenue was $13.5 million.

    -   Research and development expenses were $6.2 million.

    -   Selling, general and administrative expenses were $22.4 million.

    -   Net loss and net loss per share were $15.6 million and $0.18,
        respectively.

    -   As of December 31, 2009, cash and short-term investments were
        $57.3 million and net debt was $517.7 million.

    Selected Non-GAAP Financial Measures

    -   Certain financial measures in this press release are prepared in
        accordance with United States Generally Accepted Accounting
        Principles ("GAAP"). In addition, certain financial measures
        presented below and in the appendix to this press release are non-
        GAAP, or adjusted, financial measures that exclude certain items.
        Management uses certain non-GAAP, or adjusted, financial measures to
        establish operational goals, and believes that these measures may
        assist investors in evaluating the results of our business and
        analyzing the underlying trends in our business over time. Investors
        should consider these non-GAAP adjusted financial measures in
   
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... UK (PRWEB) March 27, 2015 The ... the back of the recession and high prices in ... market has recovered and keeps on gaining momentum now. ... NPK stands at more than 100,000 thousand tonnes. No ... years. Meantime, the global capacity rocketed during 2012-2013, registering ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... leader in liquid photopurification, announced today that the ... approval for the continued trading of SurePure ("SURP") ... execution venture marketplace for entrepreneurial and development stage ... Markets Group introduced standards and eligibility requirements designed ...
(Date:3/27/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the global pharmaceutical, biotechnology, ... Investigational New Drug (IND) application for WuXi MedImmune,s ... been accepted for review by the China Food ... September 2012, MedImmune, the global biologics research and ...
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7
... Mass. Much of the work in MIT Institute Professor ... pages of science fiction, but its products are already saving ... One of Langers specialties is growing the vital tissues of ... organs such as the liver and intestinesin a laboratory dish ...
... Conn., Feb. 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ... February 15, 2008 on its 7.75% Convertible Senior Notes,due ... Notes is $60,million., The Company paid $2,376,666.67 through ... $2,376,345.60 was paid in 5,500,800,shares of Common Stock, based ...
... ROCHESTER, N.Y., Feb. 15 EUSA Pharma (Oxford, ... has licensed OP-R003,a human anti-interleukin-6 antibody discovered by ... the product license, GSK will pay an up-front,license ... to,acquire the exclusive world-wide rights to develop and ...
Cached Biology Technology:MIT researcher addresses biomedical engineering challenges 2MIT researcher addresses biomedical engineering challenges 3Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 2Vaccinex Antibody Licensed to GlaxoSmithKline 2
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... Switching off a key DNA repair system in the developing ... as problems in brain structures vital to movement, memory and ... Research Hospital scientists. The work, published in the August ... the first evidence that cells known as cerebellar interneurons are ...
... cancer survivors who are interested in diet and exercise actually ... those survivors who do exercise and watch their diet have ... September 1, 2009 issue of Cancer , a peer-reviewed ... greater efforts are needed to encourage elderly cancer survivors to ...
... Scientists are closer to understanding how to grow replacement ... in the journal Nature Materials . Many ... stem cells, to implant into patients who have damaged or ... removed. The idea is that, ultimately, these bone-like materials could ...
Cached Biology News:Scientists track impact of DNA damage in the developing brain 2Scientists track impact of DNA damage in the developing brain 3Most older long-term cancer survivors have poor health habits 2Scientists closer to making implantable bone material, thanks to new research 2
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
P8B1...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Biology Products: